Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Florida: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 440 | 39,777 | 49% |
| 2020 | 440 | 39,834 | 52% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 12% of the cases CMS names in Florida; 208 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 65 | 3,941+8.8%/yr | +8.8%/yr | 1.61.2× | 74% | 5,860 in 2030+6.8%/yr |
| Spinal cord & DRG stimulation |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Florida · Every state · Compare with Texas
| 2024 |
| 40,806 |
| 60% |
| 2025 est. | ≈ 42,000 | – |
| 2026 est. | ≈ 43,400 | – |
| 2021 |
| 440 |
| 38,673 |
| 54% |
| 2022 | 455 | 39,611 | 56% |
| 2023 | 461 | 39,769 | 58% |
| 2024 | 451 | 40,806 | 60% |
| 2025 from claims | – | 41,979 38,525–44,414 | 61% |
| 2026 forecast | – | 43,422 38,205–50,107 | 61% |
| 2027 forecast | – | 44,741 38,249–53,318 | 61% |
| 2028 forecast | – | 46,095 38,462–56,442 | 62% |
| 2029 forecast | – | 47,484 38,783–59,549 | 62% |
| 2030 forecast | – | 48,909 39,183–62,676 | 63% |
In 2025, 5% hospital outpatient, 32% surgery center, 63% office.
| 13,392−3%/yr |
| −3%/yr |
| 14.7 |
| 91% |
| 15,000 in 2030+1.9%/yr |
| North Carolina | 172 | 11,392−0.4%/yr | −0.4%/yr | 10.9 | 82% | 12,200 in 2030+1.2%/yr |
| Virginia | 121 | 10,959+2.8%/yr | +2.8%/yr | 10.1 | 80% | 13,100 in 2030+3%/yr |
| Oklahoma | 78 | 8,975+3.6%/yr | +3.6%/yr | 17.8 | 65% | 11,900 in 2030+4.8%/yr |
| Louisiana | 95 | 8,745+0.5%/yr | +0.5%/yr | 20.3 | 63% | 10,700 in 2030+3.4%/yr |
| Maryland | 110 | 8,602−0.5%/yr | −0.5%/yr | 9.5 | 97% | 8,640 in 2030+0.1%/yr |
| Tennessee | 111 | 8,564+0.4%/yr | +0.4%/yr | 11.6 | 88% | 10,900 in 2030+4.2%/yr |
| South Carolina | 107 | 7,768−1.3%/yr | −1.3%/yr | 10.9 | 87% | 8,970 in 2030+2.4%/yr |
| Arkansas | 73 | 7,188−5.6%/yr | −5.6%/yr | 18.3 | 76% | 7,600 in 2030+0.9%/yr |
| Kentucky | 75 | 6,856−6.1%/yr | −6.1%/yr | 14.2 | 81% | 7,510 in 2030+1.5%/yr |
| Mississippi | 50 | 4,876+2%/yr | +2%/yr | 12.5 | 86% | 7,510 in 2030+7.5%/yr |
| Alabama | 71 | 4,863+1.6%/yr | +1.6%/yr | 10.5 | 74% | 6,430 in 2030+4.8%/yr |
| West Virginia | 24 | 1,871−2.4%/yr | −2.4%/yr | 8.5 | 17% | 2,300 in 2030+3.5%/yr |
| Delaware | 24 | 1,803+8.7%/yr | +8.7%/yr | 10.2 | 100% | 3,040 in 2030+9.1%/yr |
| District of Columbia | 9 | 229−7.4%/yr | −7.4%/yr | 3.5 | 96% | 240 in 2030+0.9%/yr |
| 48 |
| 1,901−2%/yr |
| −2%/yr |
| 0.80.8× |
| 65% |
| 2,240 in 2030+2.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 69% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 10 companies reported engagement with Florida’s surgeons worth $380K in consulting, speaking, meals and travel tied to these products, about $843 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.